Key result
High on-treatment platelet reactivity assessed by the VerifyNow P2Y12 test was associated with significantly higher odds of cardiovascular events in clopidogrel-treated patients (OR 3.05; 95% CI 2.33-3.98; p<0.001).
Why the study?
Does high on-treatment platelet reactivity assessed by VerifyNow P2Y12 test or CYP2C19*2 polymorphism predict cardiovascular events in clopidogrel-treated patients with cardiovascular disease?
Meta-Analysis (n=4,817)
Does high on-treatment platelet reactivity assessed by VerifyNow P2Y12 test or CYP2C19*2 polymorphism predict cardiovascular events in clopidogrel-treated patients with cardiovascular disease?
Odds Ratio: 3.05 (95% CI 2.33–3.98)
p-value: p=<0.001
High on-treatment platelet reactivity assessed by the VerifyNow P2Y12 test is strongly associated with increased adverse clinical outcomes in clopidogrel-treated patients with cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Supports VerifyNow-guided risk stratification in clopidogrel patients; confirms prognostic value but leaves practice change to RCTs.
Yamaguchi et al. (2012) conducted a meta-analysis in Cardiovascular disease (n=4,817). High on-treatment platelet reactivity (HPR) vs. Patients without HPR was evaluated on Cardiovascular events (OR 3.05, 95% CI 2.33-3.98, p=<0.001). High on-treatment platelet reactivity assessed by the VerifyNow P2Y12 test was associated with significantly higher odds of cardiovascular events in clopidogrel-treated patients (OR 3.05; 95% CI 2.33-3.98; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: